Lexeo Therapeutics (LXEO) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 17.0% versus a loss of 60.0%. Vanda Pharmaceuticals is the larger company by market cap ($276.3 million vs $265.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | VNDA |
|---|---|---|
| Share price | $3.23 | $4.57 |
| Market cap | $265.14M | $276.31M |
| 1-day change | +0.62% | +0.88% |
| YTD return | -67.67% | -48.64% |
| 1-year return | -60.02% | -17.03% |
| 5-year return | — | -75.39% |
| Forward P/E | — | 22.85 |
| EPS (TTM) | $-1.02 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $9.94 |
| 52-week low | $2.98 | $4.27 |
| Distance from 52-week high | -70.61% | -54.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +528.48% | +157.11% |
| Average volume | 1.20M | 974.13K |
| Shares outstanding | 82.09M | 60.46M |
| Employees | 63 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed LXEO by 43.0 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
LXEO vs VNDA FAQ
Which is bigger, Lexeo Therapeutics or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $276.31M compared with $265.14M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, LXEO or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and Vanda Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Lexeo Therapeutics and Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals.